We all like happy endings and this is the best kind! Just last week, rigosertib, a myelodysplastic syndrome (MDS) drug with tremendous potential, received sizable funding – the kind that will get it across and beyond the finish line. It’s a great story, made possible by LLS’s Therapy Acceleration Program (TAP), a program designed to help bridge the funding gap and accelerate the development of compounds that have the potential to change the standard of care for patients with blood cancer.
The Cliff’s Notes version:
LLS partners with Onconova Therapeutics to accelerate rigosertib and get it to myelodysplastic syndrome (MDS) patients faster.
Rigosertib does incredibly well in clinical trials and researchers learn that it may have application outside of MDS. With funding assistance from LLS, rigosertib moves into a large international clinical trial that could lead to FDA approval.
Hot off the presses! Onconova Therapeutics has granted Baxter International Inc. European licensing rights for the drug! This is great news for MDS patients as it can only help to accelerate the drug more quickly through the development pipeline.
LLS had committed up to $12.5 million for this project through TAP. Baxter bought the European rights to the compound based on the work completed thus far and has agreed to invest up to $600 million to get it to the finish line provided it continues to meet necessary milestones.
The Happy Ending
LLS’s objective in these ventures is to bridge the drug development gap and lift promising therapies to the next level of funding, and this announcement is a perfect example of our goal in action. The “Happily Ever After” will be FDA approval and widespread availability to patients (fingers crossed for those milestones mentioned above).
Please know that this happy ending was made possible by your support, and for that, we cannot thank you enough!
September is Blood Cancer Awareness Month! Follow us on Facebook to learn more about how LLS is helping create a world without blood cancer.